ARIX Arix Bioscience Plc

Arix Bioscience PLC (ARIX) 
Portfolio company Harpoon Therapeutics announces up to USD150 million private placement 
24-Oct-2023 / 07:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience plc 
 
Portfolio company Harpoon Therapeutics announces up to USD150 million private placement 
 
LONDON, 24 October 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital 
company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Harpoon 
Therapeutics ("Harpoon"), has announced it has entered into a securities purchase agreement for a private placement in 
public equity ("PIPE") financing that is expected to result in upfront gross proceeds of approximately USD100 million, 
with up to an additional approximately USD50 million of gross proceeds upon cash exercise of warrants, before deducting 
placement agent fees and offering expenses. 
 
The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset 
managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf 
Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 
HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund. 
 
Arix's holding value will continue to be determined by the market price of Harpoon's shares. 
 
Harpoon intends to use the net proceeds to fund its clinical development programs from its platforms, including ongoing 
as well as future late-stage clinical studies of HPN328. The proceeds will also be used for working capital and other 
general corporate purposes. The aggregate proceeds from this financing, combined with current cash and cash 
equivalents, are expected to be sufficient to fund the current operating plan into 2026. 
 
Robert Lyne, CEO of Arix, stated: "Following the announcement of strong data sets across Harpoon's best-in-class 
immunotherapy pipeline, we welcome this private placement alongside the addition of quality new investors on the 
register. This placement represents an additional vote of confidence by these new and existing investors, further 
underpinning Harpoon with a strong cash runway going into 2026." 
 
The full text from Harpoon's announcement is reproduced below, and can be accessed on Harpoon Therapeutics' website at: 
www.harpoontx.com. 
 
[S] 
 
Enquiries 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
+44 (0)20 7290 1050 
ir@arixbioscience.com 
 
Powerscourt Group 
Sarah MacLeod, Ibrahim Khalil, Nick Johnson 
+44 (0)20 7250 1446 
arix@powerscourt-group.com 
 
About Arix Bioscience plc 
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology 
companies around cutting-edge advances in life sciences. 
 
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help 
accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this 
exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com 
 
Harpoon Therapeutics Press Release: 
 
HARPOON THERAPEUTICS ANNOUNCES UP TO USD150 MILLION PRIVATE PLACEMENT 
 
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the 
"Company"), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has 
entered into a securities purchase agreement for a private placement in public equity ("PIPE") financing that is 
expected to result in upfront gross proceeds of approximately USD100 million, with up to an additional approximately USD50 
million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. 
The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset 
managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf 
Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 
HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund. 
 
Pursuant to terms of the securities purchase agreement, at the closing of the financing, the Company will issue an 
aggregate of 17,167,350 shares of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants 
to purchase up to an aggregate of 8,583,675 shares of its common stock, at a combined purchase price of USD5.8345 per 
share and accompanying warrant. Each full warrant will represent the right to purchase one share of the Company's 
common stock at an exercise price of USD5.8345 per share. In lieu of shares of common stock, certain investors are 
purchasing pre-funded warrants at a combined purchase price of USD5.8344 per share and accompanying warrant, which equals 
the purchase price per share of common stock and accompanying warrant, less the USD0.0001 per share exercise price of 
each pre-funded. The accompanying warrants will be exercisable upon issuance for a period of three years following the 
date of issuance. The accompanying warrants are only exercisable in cash. The PIPE financing is being conducted in 
accordance with applicable Nasdaq rules and was priced in accordance with the "Minimum Price" requirement as defined in 
the Nasdaq rules. The PIPE financing is expected to close on or about October 25, 2023, subject to satisfaction of 
customary closing conditions. 
 
The Company intends to use the net proceeds to fund its clinical development programs from its platforms, including 
ongoing as well as future late-stage clinical studies of HPN328. The proceeds will also be used for working capital and 
other general corporate purposes. The aggregate proceeds from this financing, combined with current cash and cash 
equivalents, are expected to be sufficient to fund the current operating plan into 2026. 
 
TD Cowen is acting as the lead placement agent for the PIPE financing. Canaccord Genuity and H.C. Wainwright & Co. are 
also acting as placement agents for the PIPE financing. 
 
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the 
securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable 
state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant 
to an effective registration statement or an applicable exemption from the registration requirements of the Securities 
Act and such applicable state securities laws. 
 
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor 
shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful 
prior to the registration or qualification under the securities laws of such state. 
 
About Harpoon Therapeutics 
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness 
the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are 
engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or 
antigens, carried by the target cells. Using its proprietary Tri- specific T cell Activating Construct (TriTAC®) 
platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and 
hematologic malignancies. Harpoon has also developed a proprietary ProTriTACT platform, which applies a prodrug concept 
to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. 
Harpoon's third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release 
syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com. 
 
Cautionary Note Regarding Forward-Looking Statements 
Any statements in this press release about the Company's future expectations, plans and prospects, as well as any other 
statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the 
meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties 
and actual results may differ materially from those expressed or implied by such forward-looking statements. Such 
statements include, but are not limited to, statements associated with the intended use of net proceeds from the PIPE 
financing, the Company's cash sufficiency and runway, expected timing of closing of the PIPE financing and the 
completion of the PIPE financing, and other statements containing the words "anticipates," "believes," "expects," 
"intends," "plans," "will" and similar expressions. You should not place undue reliance on forward-looking statements 
because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to 
predict and, in some cases, beyond the Company's control. These forward-looking statements are based upon the Company's 
current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results 
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result 
of various risks and uncertainties, which include, without limitation, risks associated with market conditions. These 
and other risks are described in additional detail in the Company's filings with the U.S. Securities and Exchange 
Commission (SEC). All forward-looking statements contained in this press release speak only as of the date hereof, and 

the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new 
information, future events or otherwise. 
 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCM 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   279941 
EQS News ID:    1755445 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1755445&application_name=news

(END) Dow Jones Newswires

October 24, 2023 02:00 ET (06:00 GMT)

Grafico Azioni Arix Bioscience (LSE:ARIX)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Arix Bioscience (LSE:ARIX)
Storico
Da Mag 2023 a Mag 2024